Y. Ostapenko

4.2k citations
16 papers · 2.8k · 6 hit papers · h-index 9

Impact in

  • Hepatology top 1%
    • Hepatocellular Carcinoma Treatment and Prognosis
  • Oncology top 2%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies
    • HER2/EGFR in Cancer Research
    • Colorectal Cancer Treatments and Studies

Papers in

Y. Ostapenko

14 papers receiving 2.7k citations

Y. Ostapenko's Hit Papers

Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC 2025 · 78 citations
780+2+4Years since publication2505007501k

Peers

Y. Ostapenko
Comparison fields: 5 of 57
  • Hepatology 1.1k
  • Oncology 1.2k
  • Pulmonary and Respiratory Medicine 599
  • Immunology 79
  • Cancer Research 44
Replace Рашида Вахидовна Орлова with:
Рашида Вахидовна Орлова Russia
Alejandra Negro United States
Marina Nechaeva United States
Alexander Vasilyev United States
Marina Tschaika United States
Jaekyung Cheon South Korea
Tu Van Dao Vietnam
Francisco Javier Ramírez Godinez United States
Mark Karwal United States
Yun Shen United States
Y. Ostapenko relative to Рашида Вахидовна Орлова Russia Рашида Вахидовна Орлова's profile →
Citations per field
00.5×2×3×4.5×
Рашида Вахидовна Орлова · 1×
Citations per year

Countries citing papers authored by Y. Ostapenko

Since Specialization
Citations

This map shows the geographic impact of Y. Ostapenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y. Ostapenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y. Ostapenko more than expected).

Fields of papers citing papers by Y. Ostapenko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y. Ostapenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y. Ostapenko. The network helps show where Y. Ostapenko may publish in the future.

Co-authors

The 22 scholars most cited alongside Y. Ostapenko, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Y. Ostapenko Line = papers co-authored together Y. Ostapenko links everyone, so they are left out of the graph.

All Works

16 of 16 papers shown
#Work
1
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
Hit paper breakdown →
20221109
2
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Hit paper breakdown →
2020522
3
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Hit paper breakdown →
2023446
4
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
Hit paper breakdown →
2023325
5
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Hit paper breakdown →
2024239
6
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
Hit paper breakdown →
202578
7 202446
8 202122
9 202514
10 20232
11 20181
12 20191
13 20191
14 20251
15 20240
16 20240

About Y. Ostapenko

Y. Ostapenko is a scholar working on Hepatology, Pulmonary and Respiratory Medicine, Oncology, Immunology and Epidemiology, having authored 16 papers that have together received 2.8k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Colorectal Cancer Surgical Treatments (2 papers), Lung Cancer Treatments and Mutations (1 paper), Esophageal Cancer Research and Treatment (1 paper), Cancer Immunotherapy and Biomarkers (1 paper) and Biosimilars and Bioanalytical Methods (1 paper). The work is most often cited by research in Hepatology (1.1k citations), Oncology (1.2k citations), Pulmonary and Respiratory Medicine (599 citations), Immunology (79 citations) and Cancer Research (44 citations). Y. Ostapenko has collaborated with scholars based in Ukraine, United States and South Korea. Frequent co-authors include Pooja Bhagia, Lucjan Stanislaw Wyrwicz, Patricio Eduardo Yanez, Lin Shen, Yelena Yuriy Janjigian, Mehmet Bilici, Josep M. Tabernero, Yuxian Bai, Sara Lonardi and Shukui Qin. Their work appears in journals such as Annals of Oncology, The Lancet Oncology, The Lancet, Journal of Clinical Oncology and ESMO Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact